Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week
Biogen Inc BIIB
News
Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
Biogen Completes Acquisition of RayThera Inc.
Eisai, Biogen Get FDA Approval for Treatment for Early Alzheimer's Disease
Biogen Gets FDA Breakthrough Designation for Spinraza Successor Salanersen
These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.
With Zepbound approved for sleep apnea, Lilly spends up to $7.8 billion for a company with a narcolepsy drug
Biogen will acquire a drug company for $5.6 billion to expand work in kidney diseases
Biogen Gets FDA OK of High-Dose Spinraza Regimen
Biogen Gets FDA Breakthrough Designation for Litifilimab in CLE
Walmart was too late for a Nasdaq-100 spot - but these 6 stocks made the cut
Novo Nordisk's oral GLP-1 drug didn't work on Alzheimer's as hoped, but don't call it a failure
Biogen Gets CHMP Backing for Higher-Dose Spinraza
United States